Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: A phase I, dose-finding study

European Journal of Cancer

Volumn 36, Issue 14, 2000, Pages 1773-1780

  Lortholary, A ^a   Maillard, P ^a   Delva, R ^a   Boisdron Celle, M ^a   Perard, D ^b   Vernillet, L ^b   Besenval, M ^b   Gamelin, E ^a  

^a CENTRE PAUL PAPIN   (France)

^b SANOFI   (France)

Author keywords

5 Fluorouracil; Anthracycline; Docetaxel; Metastatic breast cancer; Pharmacokinetics

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; FLUOROURACIL;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; FEMALE; HEART ARRHYTHMIA; HUMAN; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; TAXOIDS;

EID: 0033897266     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00176-3     Document Type: Article

References (29)

1. Nabholtz J.M., Senn H.J., Bezwoda W.R.et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J. Clin. Oncol. 17:1999;1413-1424.
2. Sjöström J, Mouridsen H, Pluzanska A, et al. Taxotere versus methotrexate-5-fluorouracil in patients with advanced anthracycline-resistant breast cancer: preliminary results of a randomized phase III study by Scandinavian Breast Cancer Group. Proc ASCO 1998, abstract 427.
3. Bonneterre J, Roche H, Monnier A, et al. Docetaxel versus 5 fluorouracil-vinorelbine in patients with metastatic breast cancer as second line chemotherapy: a phase III study. Proc 21st Annual San Antonio Breast Cancer Symposium 1998, abstract 223.
4. 2 as first-line chemotherapy for patients with advanced breast cancer. report of the Clinical Screening Group of the EORTC Br. J. Cancer. 74:1996;650-656.
5. Khayat D., Antoine E. Docetaxel in combination chemotherapy for metastatic breast cancer. Semin. Oncol. 24(Suppl. 13):1997;S13-S19.
6. Nabholtz J.-M., Smylie M., Mackey J.et al. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer. Oncology. 11(Suppl. 6):1997;25-27.
7. Crown J. Evolution in the treatment of advanced breast cancer. Semin. Oncol. 25(Suppl. 12):1998;12-17.
8. Petit T., Aylesworth C., Burris H.et al. A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies. Ann. Oncol. 10:1999;223-229.
9. Bissery M.-C., Nohynek G., Sanderink G.-J., Lavelle F. Docetaxel (Taxotere®): a review of preclinical and clinical experience. Part I. preclinical experience Anticancer Drugs. 6:1995;339-355.
10. Wood W.C., Budman D.R., Korzun A.H.et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast cancer. N. Engl. J. Med. 330:1994;1253-1259.
11. Vergniol J.C., Bruno R., Montay G., Frydman A. Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J. Chromatogr. 582:1992;273-278.
12. Gamelin E., Boisdron-Celle M., Turcant A., Larra F., Allain P., Robert J. Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma. J. Chromatogr. B Biomed. Sci. Appl. 695:1997;409-416.
13. Bruno R., Vivier N., Vergniol J.-C.et al. A population pharmacokinetic model for docetaxel (Taxotere®). model building and validation J. Pharmacokin. Biopharm. 24:1996;153-172.
14. Baille P., Bruno R., Schellens J.H.M.et al. Optimal sampling strategies for Bayesian estimation of docetaxel (Taxotere®) clearance. Clin. Cancer Res. 3:1997;1535-1538.
15. Bruno R., Hille D., Riva ?.et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J. Clin. Oncol. 16:1998;187-196.
16. Erlichman C., Fine S., Elhakim T. Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol. Cancer Treat. Rep. 70:1986;903-904.
17. Fleming R.A., Milano G.A., Etienne M.C. No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day) 5-FU infusion. Br. J. Cancer. 66:1992;668-672.
18. de Valeriola D, Brassinne C, Kerger J, et al. Clinical and pharmacokinetic phase I study of docetaxel combined to continuous infusion of 5-fluorouracil in advanced cancer patients. Proc ASCO 1997, abstract 221.
19. Ando M., Watanabe T., Sasaki Y.et al. A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer. Br. J. Cancer. 77:1998;1937-1943.
20. Diéras V. Review of docetaxel/doxorubicin combination in metastatic breast cancer. Oncology. 11(Suppl. 8):1997;31-33.
21. Chevallier B., Fumoleau P., Kerbrat P.et al. Association of bolus tetrahydropyranyl adriamycin and 120 hours continuous 5-fluorouracil infusion in patients with metastatic breast cancer. Am. J. Clin. Oncol. 13(Suppl. 1):1990;S40.
22. Saphner T., Tormey D.C., Carey P. Continuous-infusion 5-fluorouracil combined with doxorubicin and cyclophosphamide. feasibility study Med. Pediatr. Oncol. 20:1992;321-324.
23. Carmo-Pereira J., Costa F.O., Henriques E. Mitoxantrone, folinic acid, 5-fluorouracil and prednisone as first-line chemotherapy for advanced breast carcinoma. A phase II study. Eur. J. Cancer. 29A:1993;1814-1816.
24. Fine S., Erlichman C., Kaizer L., Warr D., Gadalla T. Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer. Breast Cancer Res. Treat. 30:1994;205-209.
25. Villalon A.H., De Guzman L.M., Samson M.C., Guancia A.A., Fernando G.Y., Romana I.B. A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at The Philippines General Hospital. Oncology. 54(Suppl. 1):1997;2-6.
26. Eisenhauer E.A. Docetaxel. current status and future prospects J. Clin. Oncol. 13:1995;2865-2868.
27. Adachi I., Watanabe T., Takashima S.et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br. J. Cancer. 73:1996;210-216.
28. Henderson I.C. Chemotherapy for metastatic disease of breast cancer. Harris J., Hellman S., Henderson I.C., Kinne D.W. Breast Disease, 2nd edn. 1991;604-665 Lippincott, Philadelphia, PA.
29. Ravdin P.M. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer. Semin. Oncol. 24(Suppl. 10):1997;S18-S21.